肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响*

doi:10.3969/j.issn.1672-5069.2025.02.014

摘要/Abstract

摘要： 目的探讨肝脏脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎(AIH)患者生化缓解和不良结局的影响。方法 2018年1月～2022年12月我院诊治的AIH患者58例,使用FibroScan 502型肝脏瞬时弹性测定仪行肝脏受控衰减参数(CAP)和肝脏硬度检测(LSM)。给予标准的泼尼松与硫唑嘌呤联合治疗观察6个月,以完全生化学缓解(CR)和不完全生化学缓解(IBR)考评疗效。应用多因素Logistic回归分析影响IBR和不良结局发生的危险因素。结果经过6个月治疗,在58例AIH患者中,35例(60.3%)获得CR,23例(39.7%)为IBR;IBR组BMI、高血压和糖尿病占比、血清球蛋白水平及CAP和LSM分别为(26.9±2.8)kg/m²、43.5%和39.1%、34.6(28.4,38.4)g/L及(275.6±16.5)dB/m和9.8(6.5,13.6) kPa,显著高于CR组【分别为(22.1±2.8)kg/m²、11.4%和5.7%、25.3(23.6,29.4)g/L及(192.0±33.5)dB/m和 5.4(2.5,8.0)kPa,P<0.05】,而血清白蛋白水平为32.4(31.6,35.7)g/L,显著低于CR组【38.3(33.6,43.7)g/L,P<0.05】;经多因素Logistic回归分析显示,CAP、肝组织重度脂肪变和LSM是发生IBR和临床不良结局的独立危险因素(P<0.05)。结论肝组织脂肪变性可能影响AIH患者标准治疗后生化学缓解,从而导致不良结局的发生,需要密切关注。

关键词: 自身免疫性肝炎, 泼尼松, 硫唑嘌呤, 肝脂肪变性, 治疗, 生化缓解

Abstract: Objective This study was conducted to explore the impact of hepatic steatosis on biochemical remission in patients with autoimmune hepatitis (AIH) receiving standardized prednisone and azathioprine therapy. Methods 58 patients with AIH were encountered in our hospital between January 2018 and December 2022, and all received standardized prednisone and azathioprine therapy for six months. At admission, all patients underwent liver biopsies, and the controlled attenuation parameter (CAP) and liver stiffness measurement were detected by FibroScan 502. The therapeutic efficacy was assessed as complete remission (CR) and insufficient biochemical remission (IBR). The influencing factors on biochemical remission and untoward outcomes were analyzed by multivariate Logistic regression. Results At the end of six month treatment, 35 patients (60.3%) responded, while 23 patients (39.7%) didn't; the body mass index, the percentages of concomitant hypertension and diabetes, serum globulin level as well as the CAP and LSM in patients with IBR were (26.9±2.8)kg/m², 43.5% and 39.1%, 34.6(28.4, 38.4)g/L, and (275.6±16.5)dB/m and 9.8(6.5, 13.6) kPa, all significantly higher than [(22.1±2.8)kg/m², 11.4% and 5.7%, 25.3(23.6, 29.4)g/L, and (192.0±33.5)dB/m and 5.4(2.5, 8.0)kPa, respectively, P<0.05], while serum albumin level was 32.4(31.6, 35.7)g/L, much lower than [38.3(33.6, 43.7)g/L, P<0.05] in patients with CR; the multivariate Logistic regression analysis showed that the CAP, severe hepatic steatosis and the LSM were all the independent risk factors for the occurrence of IBR and untoward outcomes (P<0.05) in patients with AIH. Conclusion The hepatic steatosis could impact the response to standardized therapy in patients with AIH, which might lead to the untoward outcomes and needs carefully managed in clinical practice.

Key words: Autoimmune hepatitis, Prednisone, Azathioprine, Hepatic steatosis, Therapy, Insufficient biochemical remission

管海燕, 张慧, 张毅, 王晓兰, 吴婷婷. 肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响^*[J]. 实用肝脏病杂志, 2025, 28(2): 214-217.

Guan Haiyan, Zhang Hui, Zhang Yi, et al. Impact of hepatic steatosis on biochemical remission in patients with autoimmune hepatitis receiving standardized prednisone and azathioprine therapy[J]. Journal of Practical Hepatology, 2025, 28(2): 214-217.

参考文献

[1] Dalekos GN, Gatselis NK, Zachou K, et al. NAFLD and autoimmune hepatitis: do not judge a book by its cover. Eur J Intern Med, 2020, 75: 1-9.
[2] Takahashi A, Arinaga-Hino T, Ohira H, et al. Non-alcoholic fatty liver disease in patients withautoimmune hepatitis. JGH Open, 2018, 2(2): 54-58.
[3] De Fre CH, De Fre MA, Kwanten WJ, et al.Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity? Obes Rev, 2019, 20(2): 353-363.
[4] Thuluvath PJ, Hanish S, SavvaY. Liver transplantation in cryptogenic cirrhosis: outcome comparisons between NASH, alcoholic, and AIH cirrhosis. Transplantation, 2018, 102(4): 656-663.
[5] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology, 2020, 72(2): 671-722.
[6] Muscate F, Woestemeier A, Gagliani N. Functional heterogeneity of CD4(+) T cells in liver inflammation. Semin Immunopathol, 2021, 43(4): 549-561.
[7] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(6): 1717-1730.
[8] Fan Y, Wang L, Ding Y, et al. Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients. Aging (Albany NY), 2020, 12(16): 16072-16082.
[9] Hartl J, Ehlken H, Sebode M, et al.Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol, 2018, 68(4): 754-763.
[10] Zarachi A, Pelechas E, Tsikou A, et al. Immune-mediated inner eardisease associated with type 1 autoimmune hepatitis: a challenging coexistence. Mediterr J Rheumatol, 2022, 33(3): 349-360.
[11] Chen Q, Gao M, Yang H, et al.Serum ferritin levels are associated with advanced liver fibrosis in treatment-naive autoimmune hepatitis. BMC Gastroenterol, 2022, 22(1): 23.
[12] Eslam M, Sarin SK, Wong VW, et al. The Asian-Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int, 2020, 14(6): 889-919.
[13] Chen Q, Zhao L, Mei L, et al.Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. Dig Liver Dis, 2022, 54(3): 378-384.
[14] Pape S, Snijders R, Gevers TJG, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the international autoimmune hepatitis group. J Hepatol, 2022, 76(4): 841-849.
[15] Liberal R, de Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis. Lancet Gastroenterol Hepatol, 2021, 6(4): 315-326.
[16] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci, 2019, 76(1): 99-128.
[17] Zeng Q, Zhao L, Meng C, et al.Prophylactic and therapeutic effects of different doses of vitamin C on high-fat-diet-induced non-alcoholic fatty liver disease in mice. Biomed Pharmacother, 2020, 131: 110792.
[18] Fu T, Chen Y, Li J, et al.Exploring the effective components and mechanism of action of Japanese ardisia in the treatment of autoimmune hepatitis based on network pharmacology and experimental verification. Pharmaceuticals (Basel), 2022, 15(12):534-538.
[19] Snijders R, Stoelinga AEC, Gevers TJG, et al. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (Camaro trial): study protocol for a randomised controlled trial. Trials, 2022, 23(1): 1012.
[20] Engel B, Jaeckel E, Taubert R. No association of serum ferritin levels with advanced liver fibrosis in untreated German patients with autoimmune hepatitis. BMC Gastroenterol, 2022, 22(1): 528.

肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响^*

Impact of hepatic steatosis on biochemical remission in patients with autoimmune hepatitis receiving standardized prednisone and azathioprine therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕天富, 南琼. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展[J]. 实用肝脏病杂志, 2025, 28(2): 165-168.
[2]	陈婷婷, 丁蓉, 姬文莉, 吴梦秋. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用^*[J]. 实用肝脏病杂志, 2025, 28(2): 178-181.
[3]	钱花, 杨忠祥, 石荔. 核苷(酸)类似物经治的慢性乙型肝炎患者发生低病毒血症影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 186-189.
[4]	祁婧, 赵小婷, 王婷婷, 高瑞. 接受索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血清NOD样受体热蛋白结构域相关蛋白3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 194-197.
[5]	钱平安, 姜煜资, 聂红明. 穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 206-209.
[6]	孙超, 宋丽萍, 王彬. 异甘草酸镁联合还原型谷胱甘肽治疗化疗药物性肝损伤患者疗效及其血清氧化应激指标的变化研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 222-225.
[7]	何晓非, 陈杰, 赵斌, 陆世峰. 选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 238-241.
[8]	拾倩, 李莉, 倪昊天. 替诺福韦联合安络化纤丸治疗乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 242-245.
[9]	程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰. 脾栓塞术治疗肝豆状核变性并发中重度脾功能亢进症患者疗效评价^*[J]. 实用肝脏病杂志, 2025, 28(2): 250-253.
[10]	陈思雨, 庞永平, 宋云鹏, 乔海霞. TACE联合靶向和免疫治疗中晚期肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 258-261.
[11]	严隽瑶, 尹国文, 徐清宇, 尤然, 秦锦霞. 阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 262-265.
[12]	钟新梅, 闫莉莉, 张冬梅. 细菌性肝脓肿患者临床特征与病原菌分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 286-289.
[13]	翟鹏, 张华国, 蒋永军. 腹腔镜与胆道镜双镜联合治疗复发性胆总管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 306-309.
[14]	孙福荣, 王炳元. 酒精性肝病患者酒精应用障碍管理[J]. 实用肝脏病杂志, 2025, 28(1): 1-4.
[15]	王菲, 刘迎宾, 赵媛媛. 聚乙二醇干扰素α-2a联合艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 40-43.